Disease Site: GI Cancers-Miscellaneous

NCT05677490 | A022102 | ALLIANCE

A randomized phase III trial of mFOLFIRINOX +/- nivolumab vs. FOLFOX +/- nivolumab for first-line treatment of metastatic HER2-negative gastroesophageal adenocarcinoma